Sgnlva-005: Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced aerodigestive tract malignancies

被引：0
|
作者：
Anderson, Ian Churchill
Wang, Yinghui
Wang, Zejing
Sanborn, Rachel E.
机构：
[1] St Joseph Heritage Healthcare, Santa Rosa, CA USA
[2] Seattle Genet Inc, Bothell, WA USA
[3] Providence Canc Inst, Earle A Chiles Res Inst, Portland, OR USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS469
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations
    Doraiswamy, Anu
    Jayaprakash, Vijayvel
    Kania, Marek
    Hahka-Kemppinen, Marjo
    Yang, Zhao
    Rudinski, Mark
    Ravandi, Farhad
    BLOOD, 2021, 138
  • [42] Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma
    Garcia, Jairo A.
    Roberts, Lewis R.
    JOURNAL OF HEPATOLOGY, 2012, 56 (02) : 486 - 487
  • [43] An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967)
    Xu, J.
    Li, J.
    Bai, C. M.
    Xu, N.
    Zhou, Z. W.
    Li, Z. P.
    Zhou, C. C.
    Wang, W.
    Li, J.
    Qi, C.
    Hua, Y.
    Su, W. G.
    NEUROENDOCRINOLOGY, 2017, 105 : 228 - 228
  • [44] Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
    Park, Joong-Won
    Finn, Richard S.
    Kim, Jun Suk
    Karwal, Mark
    Li, Ruby K.
    Ismail, Fuad
    Thomas, Melanie
    Harris, Rosemarie
    Baudelet, Christine
    Walters, Ian
    Raoul, Jean-Luc
    CLINICAL CANCER RESEARCH, 2011, 17 (07) : 1973 - 1983
  • [45] Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
    Matsubara, Nobuaki
    Kusuhara, Shota
    Yamamoto, Noboru
    Sudo, Kazuki
    Yanagita, Masahiko
    Murayama, Kosho
    Kawasumi, Hisashi
    Russell, Deanna L.
    Yin, Da
    Shimizu, Toshio
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (04) : 341 - 352
  • [46] A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
    Jeffrey P. Sharman
    Jennifer J. Wheler
    Lawrence Einhorn
    Afshin Dowlati
    Geoffrey I. Shapiro
    John Hilton
    John M. Burke
    Tanya Siddiqi
    Nancy Whiting
    Shadia I. Jalal
    Investigational New Drugs, 2019, 37 : 738 - 747
  • [47] Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
    Tanizaki, J.
    Yonemori, K.
    Akiyoshi, K.
    Minami, H.
    Ueda, H.
    Takiguchi, Y.
    Miura, Y.
    Segawa, Y.
    Takahashi, S.
    Iwamoto, Y.
    Kidera, Y.
    Fukuoka, K.
    Ito, A.
    Chiba, Y.
    Sakai, K.
    Nishio, K.
    Nakagawa, K.
    Hayashi, H.
    ANNALS OF ONCOLOGY, 2022, 33 (02) : 216 - 226
  • [48] Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme
    Aida Muhic
    Hans Skovgaard Poulsen
    Morten Sorensen
    Kirsten Grunnet
    Ulrik Lassen
    Journal of Neuro-Oncology, 2013, 111 : 205 - 212
  • [49] Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme
    Muhic, Aida
    Poulsen, Hans Skovgaard
    Sorensen, Morten
    Grunnet, Kirsten
    Lassen, Ulrik
    JOURNAL OF NEURO-ONCOLOGY, 2013, 111 (02) : 205 - 212
  • [50] A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
    Sharman, Jeffrey P.
    Wheler, Jennifer J.
    Einhorn, Lawrence
    Dowlati, Afshin
    Shapiro, Geoffrey I.
    Hilton, John
    Burke, John M.
    Siddiqi, Tanya
    Whiting, Nancy
    Jalal, Shadia I.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 738 - 747
12345